HighLife Receives IDE Approval to Initiate US Pivotal Clinical Study for treatment of Mitral Regurgitation
DAIC
JUNE 3, 2024
milla1cf Mon, 06/03/2024 - 12:36 June 3, 2024 — HighLife SAS , a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe Mitral Regurgitation (MR), announced today that the U.S. I am honored to lead the HighLife pivotal study.
Let's personalize your content